Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Nanocarrier-mediated drug delivery systems for spinal cord injury treatment

Cheng Y., Wang R., Zhou X., Jiang H., Li M., Wei X.

Narrative Review on Spinal Cord Injury, published in Front Bioeng Biotechnol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Bioeng Biotechnol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40979635
PMCID
PMC12447078
DOI
10.3389/fbioe.2025.1660264

Abstract (original English)

Spinal cord injury is a severe neurological condition that frequently. Results in lasting motor and sensory dysfunction. Traditional drug therapies have shown limited efficacy in addressing the complexities of spinal cord injury. This limitation highlighting the urgent need for innovative treatment strategies. In recent years, nanocarrier-mediated systems have garnered significant attention due to their superior drug delivery capabilities and targeting precision. This review summarizes the latest advancements in the application of nanocarriers for the treatment of spinal cord injuries, discussing various types of nanocarriers, drug loading and capacity and release profiles, as well as targeted delivery strategies. The insights aim to establish a theoretical foundation for future research and clinical applications in this critical area of medicine.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research